PentixaPharm lands Series A
PentixaPharm, a developer of CXCR4-targeted theranostics, has secured 15 million euros in Series A financing.
PentixaPharm, a developer of CXCR4-targeted theranostics, has secured 15 million euros in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination
